Check the complete subject-wise syllabus, important topics, and exam pattern for the Lower PCS exam. Download the detailed ...

Read Live Breaking News from India along with Latest News and Today's Top Headlines Online in Bharat. Stay Up-to-date with Top news in India, current headlines, photos & videos online, live coverage ...

Marc Cummings, president and CEO of Life Science Washington, speaking at a one-day forum focused on AI-driven biotech that was held in Seattle in October 2025. (Life Science Washington Photo) Seattle ...

The Consortium of Medical, Engineering and Dental Colleges of Karnataka Undergraduate Entrance Test (UGET) 2026 registration process will close today,.

Biotech stocks saw a major rebound in 2025, with key indexes significantly outperforming the S&P 500. Private investment in longevity science doubled in 2024, highlighting growing interest in ...

Molecular glue-focused biotech f5 Therapeutics has failed to stick around for the long haul, shuttering after six years, according to an announcement from the company’s CEO on LinkedIn. “The past few ...

Florida State University faculty must now publish course syllabi 45 days before classes begin. The FSU Board of Trustees approved the change to comply with a state directive. Faculty expressed ...

There are hundreds of biotechnology companies today that have never commercialized a drug. For many years, the standard approach in the industry has been to advance the science, prove the asset, and ...

Lizzi C. Lee is a fellow on the Chinese economy at Asia Society Policy Institute’s Center for China Analysis (CCA), based in Washington DC, USA. Jing Qian is vice-president of the Asia Society and ...

Debut has a new ingredient and is working with skin care brands on formulations. The biotech beauty company is launching DermCeutical EDL, a topical bioactive ingredient that claims to deliver ...

Arthur Herman’s op-ed, “America Is the Sole Superpower Again,” (Jan. 15) asserts that China is “sliding into a distant second place” in the battle for economic, military and technological supremacy.

A run of pharmaceutical mergers and acquisitions is fueling optimism that biotechnology venture capital is poised to rebound from its postpandemic slump. With $223 billion in biotech M&A deals ...